1. Schrí¶der FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Mí¤í¤ttí¤nen ML, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A, for the ERSPC Investigators Screening and Prostate-Cancer Mortality in a Randomized European Study. N Engl J Med 2009: 360:1320-1328,

2. Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O"™Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC and for the PLCO Project Team. Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up. JNCI J Natl Cancer Inst 2012: 104(2): 125-132,

3. Editorial BJU International 2011: 108(11): 1679"“1938, E315"“E317,

4. Crawford ED, Moul JM, Rove KO, Pettaway CA, Lamerato LE, Hughes A.: Prostate-specific antigen 1.5"“4.0 ng/mL: a diagnostic challenge and danger zone. BJU International 2011: 108(11):1743"“1749

5. Loeb S, Catalona WJ. What to do with abnormal PSA Test. The Oncologist 2008: 13 Nº 3, 299-305

6. Fang J, Metter EJ, Landis P, Chan DW, Morrell CH, Carter HB. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology. 2001: 58:411"“416,

7. Balk SP, Ko YJ, Bubley GJ. Biology of Prostate-Specific Antigen. Journal of Clinical Oncology 2003: 28 (2): 383-91

8. Instituto Nacional del Cáncer de los Estados Unidos de Norteamerica (CNI) 2012 http://www.cancer.gov/espanol/recursos/hojas- informativas/deteccion-diagnostico/marcadores-de-tumores (consultado Mayo 18, 2012)

9. Vis AN, Schí¶der FH, Van der Kwast TH. Characteristics of prostate cancer in different prostate‐specific antigen ranges. In: Kurth KH, Mickisch GH, Schrí¶der FH, Editores. Renal, bladder, prostate and testicular cancer, an update. New York: The Parthenon Publishing Group Inc; 97‐111, 2000

10. Vis AN, Kranse R, Roobol M, Van der Kwast TH, Schrí¶der FH. Serendipity in detecting disease in low prostate‐specific antigen ranges. BJU Int 2002: 89(4):384‐389,

11. Dong F, Kattan MW, Steyerberg EW, et al. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. J Urol 2008: 180(1):150-4,

12. Potenziani Bigelli JC. Conferencia "˜Perla Médica"™ Estatus del PSA Enfoque 2012 dada el 3 de Mayo 2012. Academia Nacional de Medicina

13. Smith DS, Humphrey PA, Catalona WJ. The early detection of prostate carcinoma with prostate specific antigen: The Washington University experience. Cancer 1997: 80(9):1853"“1856,

14. Roxanne Nelson. "˜PSA Testing Continues to Polarize Medical Community"™ Medscape Medical News Oncology Cancer Epidemiol Biomarkers Prev. 2012;21:391‐394, 395‐397

15. Nick Mulcahy "˜PSA Test Is Imperfect Screening Tool: What to Do? Medscape Today News 1 de octubre del 2009

16. Prostate-Specific Antigen Best Practice Statement 2009 Update. http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-eports/psa09.pdf (consultado Mayo 18, 2012)

17. McNeal J. Regional Morphology and pathology of the prostate. American Journal of Clinical Pathology 1968; 49, 347-357,

18. Kirby R, Christmas T. Benign Prostatic Hyperplasia. Gower Medical Publishing 1993

19. Nelson W, De Marzo A, Isaacs W. Prostate Cancer. Mechanisms of Disease. NEJM 2003; 349:366-381,

20. Oliveira Paula A, Aura Colaí§o, Raquel Chaves, Henrique Guedes-Pinto, Luis F. De-La-Cruz P, Carlos Lopes. Chemical carcinogenesis. An. Acad. Bras. Ciíªnc. 2007; 79(4): 593-616,

21. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. European Urology Supplements 2006; 5:698-703,

22. De Marzo AM, DeWeese TL, Platz EA, Meeker AK, Nakayama M, Epstein JI, Issacs WB, Nelson WG. Pathological and Molecular Mechanisms of Prostate Carcinogénesis: Implications for diagnosis, detection, prevention and treatment.. Journal of Cellular Biochemistry 2004; 91:459-477,

23. Roehrborn CG, Boyle P, Bergner D, Gray T, Gittelman M, Shown T, Melman A, Bracken RB, deVere White R, Taylor A, Wang D, Waldstreicher J. Serum prostate-specific antigen and prostate volume predict long-term outcome in symptoms and flow rate: results of a 4- year, randomized trial comparing finasteride vs placebo. PLESS Study Group. Urology. 1999; 54:662"“669,

24. Madersbacher S, Marszalek M, Lackner J, Berger P, Schatzl G.The long-term outcome of medical therapy for BPHEur Urol. 2007; 51(6):1522-33,

25. AUA Practice Guidelines Committee. J Urol 2003; 170: 530"“54,

26. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines) Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ. EAU BPH Guidelines. Eur Urol 2004; 46:547"“54,

27. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.Urology 1999; 53:581-589,

28. Roehrborn CG, McConnell JD, Lieber M, Kaplan S, Geller J, Malek GH, Castellanos R, Coffield S, Saltzman B, Resnick M, Cook TJ, Waldstreicher J. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology 1999; 53:473"“80,

29. Jepsen JV, Bruskewitz RC. In: Lepor H (ed). Prostatic Diseases. WB Saunders, 127"“142, 2000

30. Roehrborn CG, Sherwood JB, McConnell JD, Vazquez DJ, Lin VK. Heterogeneity of 5 alpha-reductase gene expression in benign prostatic hyperplasia J Urol. 2003; 169(2):575-9,

31. Partin AW, Freedland SJ. Detecting Prostate Cancer with Molecular Markers: uPM3. Rev Urol 2005; 7(4):236-8,

32. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 20;279(19):1542-7,

33. Loeb S, Catalona WJ. What to do with an abnormal PSA test. The Oncologist 2008; 13(3), 299-305,

34. Nickel JC, Elhilali M, Vallancien G; ALF-ONE Study Group Benign prostatic hyperplasia (BPH) and prostatitis: prevalence of painful ejaculation in men with clinical BPH. BJU International 2005; 95(4): 571-574,

35. Tuxhorn JA, GE Ayala, MJ Smith, VC Smith, Dang TD, RD Rowley. Estroma reactivo en el cáncer de próstata humano: la inducción del fenotipo miofibroblastos y la remodelación de la matriz extracelular. Clin Cancer Res. 2002; 8 (9) :2912-23,

36. A. Heidenreich, M. Bolla, S. Joniau, Mason, V. Matveev, N. Mottet, H-P. Schmid, T.H. van der Kwast, T. Wiegel, F. Zattoni Guí­a clí­nica sobre el cáncer de próstata.. European Association of Urology 2010 http://www.aeu.es/UserFiles/01GUIA_CLINICA_SOBRE_EL_CANCER_ DE_PROSTATA.pdf (consultado Mayo 18, 2012)

37. Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K, DeSantis C, Smith RA; American Cancer Society Prostate Cancer Advisory Committee. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010; 60(2):70-98,

38. National Comprehensive Cancer Network Guidelines. Prostate Cancer Early Detection, Version I. 2011. https://subscriptions.nccn.org/gl_login.aspx?ReturnURL=http://www. nccn.org/professionals/physician_gls/pdf/prostate.pdf (consultado Mayo 18, 2012)

39. Prostate-Specific Antigen Best Practice Statement: 2009 Update. American Urological Association. http://www.auanet.org/content/media/psa09.pdf. (consultado Mayo 18, 2012)